Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

Antibody validation

Your experiments need well-validated, high quality antibodies.

All of our antibodies go through a rigorous validation procedure to ensure the highest quality products come to your bench. Repeatable, consistent results are key to success of your research.

Antibody Validation

In the dynamic world of scientific research and biotechnology, the specificity and reliability of antibodies are paramount. Whether you are a seasoned university professor, a postdoctoral researcher, an eager undergraduate, or representing a biotech company engaged in basic, diagnostic, or clinical research, working with validated antibodies increases the chances of success in your scientific endeavors.

The Importance of Antibody Validation

Antibodies are indispensable tools in numerous research applications, from understanding fundamental biological processes to diagnosing diseases and developing new therapies. Antibody validation confirms that an antibody is specific, sensitive, reliable, and fit for its intended purpose. It minimizes the risk of using flawed reagents in Western blotting, immunohistochemistry, flow cytometry, and ELISA experiments, ultimately leading to more robust and trustworthy scientific conclusions. Indeed, unvalidated antibodies can lead to false-positive or false-negative results, wasted resources, and skewed interpretations of experimental data. Additionally, a study co-authored by NeoBiotechnologies’ CEO, Dr. Atul K. Tandon, reported that 78% of monoclonal antibodies they analyzed were not monospecific, debunking the belief that all monoclonals are always monospecific and emphasizing the importance of antibody validation (Bradbury et al. 2018)1.

NeoBiotechnologies’ Standard of Antibody Validation

At NeoBiotechnologies, we are committed to upholding the highest standards of antibody validation to meet the diverse needs of the scientific community. We employ cutting-edge techniques and continually invest in research and development to enhance antibody validation methods. Our comprehensive validation process includes SDS-PAGE, mycoplasma cleaning, IHC on FFPE tissues [link], Western blotting [link], and Human protein arrays [link]. We validate our products for the applications listed by performing redundant tests on the antibodies and performing rigorous quality control to ensure monospecificity. Our antibodies undergo thorough assessments to ensure specificity and optimal performance across various applications. Furthermore, we conduct an additional level of validation, known as Enhanced Validation, in accordance with the guidelines outlined by the International Working Group for Antibody Validation (IWGAV) as published in Nature Methods (Uhlen et al. 2016)2.

Enhanced validation

At NeoBiotechnologies, we leverage both Protein Array analysis and Tissue Microarrays (TMAs) as powerful tools in our antibody validation process. The HuProt platform enables comprehensive testing against a vast array of human proteins, ensuring rigorous confirmation of antibody specificity. Similarly, TMAs allow for high-throughput screening across diverse tissues, ensuring comprehensive evaluation and reliable assessment of antibody specificity. Explore the significance of our enhanced validation techniques below.

Application validation

Additionally, we assist in confirming the functionality of the antibody in specific application(s) of interest. Application verification is employed to guarantee the antibody’s efficacy not only in a singular application but also across various other applications, demonstrating its accurate target binding. Our expertise spans a broad spectrum of applications, encompassing western blot, flow cytometry, ChIP assays, immunocytochemistry (ICC), and immunohistochemistry (IHC). Explore each application below to access a typical protocol utilized for application verification.


One aspect that sets NeoBiosciences apart from other antibody manufacturers is that we sequence all our products. This added quality control step ensures reproducibility and lot-to-lot consistency. Furthermore, it facilitates potential partnerships and licensing.

  1. Bradbury, Andrew R. M., Nathan D. Trinklein, Holger Thie, Ian C. Wilkinson, Atul K. Tandon, Stephen Anderson, Catherine L. Bladen, et al. 2018. “When Monoclonal Antibodies Are Not Monospecific: Hybridomas Frequently Express Additional Functional Variable Regions.” mAbs 10 (4): 539–46. https://doi.org/10.1080/19420862.2018.1445456. ↩︎
  2. Uhlen, M., Bandrowski, A., Carr, S. et al. A proposal for validation of antibodies. Nat Methods 13, 823–827 (2016). https://doi.org/10.1038/nmeth.3995 ↩︎

We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.